Antibody distance from the cell membrane regulates antibody effector mechanisms

Journal of Immunology

Volumn 198, Issue 10, 2017, Pages 3999-4011

  Cleary, Kirstie L S ^a   Chan, H T Claude ^a   James, Sonja ^a   Glennie, Martin J ^a   Cragg, Mark S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD137 ANTIGEN; CD20 ANTIGEN; CD52 ANTIGEN; EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RITUXIMAB; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENETIC TRANSFECTION; IN VIVO STUDY; LIVER; LYMPH NODE; MOLECULAR CLONING; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; TUMOR CELL; WESTERN BLOTTING; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD20; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL MEMBRANE; EPITOPES; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY; MICE; PHAGOCYTOSIS;

EID: 85019688652     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601473     Document Type: Article

References (64)

1. Molina, A. 2008. A decade of rituximab: Improving survival outcomes in non- Hodgkin's lymphoma. Annu. Rev. Med. 59: 237-250.
2. Weiner, L. M., J. C. Murray, and C. W. Shuptrine. 2012. Antibody-based immunotherapy of cancer. Cell 148: 1081-1084.
3. Ivanov, A., S. A. Beers, C. A. Walshe, J. Honeychurch, W. Alduaij, K. L. Cox, K. N. Potter, S. Murray, C. H. Chan, T. Klymenko, et al. 2009. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 119: 2143-2159.
4. Alduaij, W., A. Ivanov, J. Honeychurch, E. J. Cheadle, S. Potluri, S. H. Lim, K. Shimada, C. H. Chan, A. Tutt, S. A. Beers, et al. 2011. Novel type II anti- CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 117: 4519-4529.
5. Oldham, R. J., K. L. Cleary, and M. S. Cragg. 2014. CD20 and its antibodies: Past, present, and future. For. Immunopathol. Dis. Therap. 5: 7-23.
6. Borsos, T., and H. J. Rapp. 1965. Complement fixation on cell surfaces by 19S and 7S antibodies. Science 150: 505-506.
7. Diebolder, C. A., F. J. Beurskens, R. N. de Jong, R. I. Koning, K. Strumane, M. A. Lindorfer, M. Voorhorst, D. Ugurlar, S. Rosati, A. J. Heck, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260-1263.
8. van Lookeren Campagne, M., C. Wiesmann, and E. J. Brown. 2007. Macrophage complement receptors and pathogen clearance. Cell. Microbiol. 9: 2095-2102.
9. Müller-Eberhard, H. J. 1986. The membrane attack complex of complement. Annu. Rev. Immunol. 4: 503-528.
10. Bruhns, P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
11. Cullen, S. P., and S. J. Martin. 2008. Mechanisms of granule-dependent killing. Cell Death Differ. 15: 251-262.
12. Freeman, S. A., J. Goyette, W. Furuya, E. C. Woods, C. R. Bertozzi, W. Bergmeier, B. Hinz, P. A. van der Merwe, R. Das, and S. Grinstein. 2016. Integrins form an expanding diffusional barrier that coordinates phagocytosis. Cell 164: 128-140.
13. Berón, W., C. Alvarez-Dominguez, L. Mayorga, and P. D. Stahl. 1995. Membrane trafficking along the phagocytic pathway. Trends Cell Biol. 5: 100-104.
14. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
15. López-Albaitero, A., S. C. Lee, S. Morgan, J. R. Grandis, W. E. Gooding, S. Ferrone, and R. L. Ferris. 2009. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol. Immunother. 58: 1853-1864.
16. Gül, N., L. Babes, K. Siegmund, R. Korthouwer, M. Bögels, R. Braster, G. Vidarsson, T. L. ten Hagen, P. Kubes, and M. van Egmond. 2014. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124: 812-823.
17. Tipton, T. R., A. Roghanian, R. J. Oldham, M. J. Carter, K. L. Cox, C. I. Mockridge, R. R. French, L. N. Dahal, P. J. Duriez, P. G. Hargreaves, et al. 2015. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 125: 1901-1909.
18. Shim, H. 2011. One target, different effects: A comparison of distinct therapeutic antibodies against the same targets. Exp. Mol. Med. 43: 539-549.
19. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P.W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
20. Cragg, M. S., and M. J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743.
21. Teeling, J. L., W. J. Mackus, L. J. Wiegman, J. H. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371.
22. Beers, S. A., C. H. Chan, S. James, R. R. French, K. E. Attfield, C. M. Brennan, A. Ahuja, M. J. Shlomchik, M. S. Cragg, and M. J. Glennie. 2008. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximablike) reagents in B-cell depletion regardless of complement activation. Blood 112: 4170-4177.
23. Reichert, J. M. 2017. Therapeutic monoclonal antibodies approved or in review in the European Union or the United States. The Antibody Society. Available at: Http://www.antibodysociety.org/news/approved-antibodies/. Accessed: January 23, 2017.
24. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98: 3383-3389.
25. Derer, S., P. Bauer, S. Lohse, A. H. Scheel, S. Berger, C. Kellner, M. Peipp, and T. Valerius. 2012. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector
26. Bindon, C. I., G. Hale, and H. Waldmann. 1988. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. 18: 1507-1514.
27. Treumann, A., M. R. Lifely, P. Schneider, and M. A. Ferguson. 1995. Primary structure of CD52. J. Biol. Chem. 270: 6088-6099.
28. Cho, H. S., K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, D. W. Denney, Jr., and D. J. Leahy. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
29. Haso,W., D. W. Lee, N. N. Shah, M. Stetler-Stevenson, C. M. Yuan, I. H. Pastan, D. S. Dimitrov, R. A. Morgan, D. J. FitzGerald, D. M. Barrett, et al. 2013. Anti- CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165-1174.
30. Varghese, B., A. Widman, J. Do, B. Taidi, D. K. Czerwinski, J. Timmerman, S. Levy, and R. Levy. 2009. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood 114: 4477-4485.
31. Kearney, J. F., A. Radbruch, B. Liesegang, and K. Rajewsky. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550.
32. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. Gene 77: 61-68.
33. Sanchez, A. B., T. Nguyen, R. Dema-Ala, A. C. Kummel, T. J. Kipps, and B. T. Messmer. 2010. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother. Pharmacol. 66: 919-925.
34. Perosa, F., E. Favoino, M. A. Caragnano, and F. Dammacco. 2006. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinaselike phosphodiesterase 3b precursor. Blood 107: 1070-1077.
35. Won, E. Y., K. Cha, J. S. Byun, D. U. Kim, S. Shin, B. Ahn, Y. H. Kim, A. J. Rice, T. Walz, B. S. Kwon, and H. S. Cho. 2010. The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J. Biol. Chem. 285: 9202-9210.
36. Beum, P. V., M. A. Lindorfer, and R. P. Taylor. 2008. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximabopsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 181: 2916-2924.
37. Xia, M. Q., M. Tone, L. Packman, G. Hale, and H. Waldmann. 1991. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur. J. Immunol. 21: 1677-1684.
38. Xia, M. Q., G. Hale, M. R. Lifely, M. A. Ferguson, D. Campbell, L. Packman, and H.Waldmann. 1993. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositolanchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. 293: 633-640.
39. Zent, C. S., C. R. Secreto, B. R. LaPlant, N. D. Bone, T. G. Call, T. D. Shanafelt, D. F. Jelinek, R. C. Tschumper, and N. E. Kay. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk earlyintermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32: 1849-1856.
40. Dyer, M. J., G. Hale, F. G. Hayhoe, and H. Waldmann. 1989. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73: 1431-1439.
41. Hu, Y., M. J. Turner, J. Shields, M. S. Gale, E. Hutto, B. L. Roberts, W. M. Siders, and J. M. Kaplan. 2009. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128: 260-270.
42. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
43. James, L. C., G. Hale, H. Waldmann, and A. C. Bloomer. 1999. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. [Published erratum appears in 1999 J. Mol. Biol. 292: 1161.] J. Mol. Biol. 289: 293-301.
44. Chen, R., J. J. Knez, W. C. Merrick, and M. E. Medof. 2001. Comparative efficiencies of C-terminal signals of native glycophosphatidylinositol (GPI)- anchored proproteins in conferring GPI-anchoring. J. Cell. Biochem. 84: 68-83.
45. Bournazos, S., S. P. Hart, L. H. Chamberlain, M. J. Glennie, and I. Dransfield. 2009. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J. Immunol. 182: 8026-8036.
46. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
47. Brüggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166: 1351-1361.
48. Niederfellner, G., A. Lammens, O. Mundigl, G. J. Georges, W. Schaefer, M. Schwaiger, A. Franke, K. Wiechmann, S. Jenewein, J. W. Slootstra, et al. 2011. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 118: 358-367.
49. Banner, D. W., A. D'Arcy, W. Janes, R. Gentz, H. J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73: 431-445.
50. Shuford, W. W., K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W. Siadak, T. J. Brown, J. Emswiler, H. Raecho, C. P. Larsen, et al. 1997. 4- 1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55.
51. Wyzgol, A., N. Müller, A. Fick, S. Munkel, G. U. Grigoleit, K. Pfizenmaier, and H. Wajant. 2009. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 183: 1851-1861.
52. Nam, K. O., H. Kang, S. M. Shin, K. H. Cho, B. Kwon, B. S. Kwon, S. J. Kim, and H. W. Lee. 2005. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J. Immunol. 174: 1898-1905.
53. Wallis, R., D. A. Mitchell, R. Schmid, W. J. Schwaeble, and A. H. Keeble. 2010. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 215: 1-11.
54. de Jong, R. N., F. J. Beurskens, S. Verploegen, K. Strumane, M. D. van Kampen, M. Voorhorst, W. Horstman, P. J. Engelberts, S. C. Oostindie, G. Wang, et al. 2016. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG Hexamers at the cell surface. PLoS Biol. 14: E1002344.
55. Vidarsson, G., G. Dekkers, and T. Rispens. 2014. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 5: 520.
56. Natsume, A., M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, and R. Niwa. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68: 3863-3872.
57. Davis, S. J., and P. A. van der Merwe. 2006. The kinetic-segregation model: TCR triggering and beyond. Nat. Immunol. 7: 803-809.
58. Choudhuri, K., D. Wiseman, M. H. Brown, K. Gould, and P. A. van der Merwe. 2005. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 436: 578-582.
59. Rudd, P. M., B. P. Morgan, M. R. Wormald, D. J. Harvey, C. W. van den Berg, S. J. Davis, M. A. Ferguson, and R. A. Dwek. 1997. The glycosylation of the complement regulatory protein, human erythrocyte CD59. J. Biol. Chem. 272: 7229-7244.
60. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood 115: 5191-5201.
61. Ruffell, B., N. I. Affara, and L. M. Coussens. 2012. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33: 119-126.
62. Simpson, T. R., F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, et al. 2013. Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210: 1695-1710.
63. Marson, A., K. Kretschmer, G. M. Frampton, E. S. Jacobsen, J. K. Polansky, K. D. MacIsaac, S. S. Levine, E. Fraenkel, H. von Boehmer, and R. A. Young. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931-935.
64. McHugh, R. S., M. J. Whitters, C. A. Piccirillo, D. A. Young, E. M. Shevach, M. Collins, and M. C. Byrne. 2002. CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.